Biogen Inc (NASDAQ:BIIB) Director Alexander J. Denner purchased 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 30th. The shares were purchased at an average price of $324.86 per share, for a total transaction of $9,745,800.00. Following the completion of the acquisition, the director now owns 10,909 shares of the company’s stock, valued at approximately $3,543,897.74. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

BIIB stock opened at $330.91 on Monday. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.32 and a quick ratio of 2.46. Biogen Inc has a one year low of $249.17 and a one year high of $388.67. The company has a market capitalization of $66.67 billion, a price-to-earnings ratio of 12.63, a P/E/G ratio of 1.12 and a beta of 1.14.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Tuesday, January 29th. The biotechnology company reported $6.99 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $6.72 by $0.27. Biogen had a net margin of 32.94% and a return on equity of 40.53%. The company had revenue of $3.53 billion during the quarter, compared to analysts’ expectations of $3.39 billion. During the same quarter in the prior year, the company earned $5.26 EPS. The firm’s revenue was up 6.6% on a year-over-year basis. As a group, equities research analysts forecast that Biogen Inc will post 28.55 earnings per share for the current fiscal year.

Several institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC boosted its stake in shares of Biogen by 6.5% in the 3rd quarter. AQR Capital Management LLC now owns 3,024,037 shares of the biotechnology company’s stock valued at $1,068,422,000 after purchasing an additional 183,542 shares in the last quarter. Capital World Investors boosted its stake in shares of Biogen by 503.2% in the 3rd quarter. Capital World Investors now owns 2,473,708 shares of the biotechnology company’s stock valued at $873,986,000 after purchasing an additional 2,063,598 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Biogen by 3.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 2,362,136 shares of the biotechnology company’s stock valued at $685,588,000 after purchasing an additional 72,668 shares in the last quarter. Jackson Square Partners LLC boosted its stake in shares of Biogen by 5.7% in the 3rd quarter. Jackson Square Partners LLC now owns 2,241,778 shares of the biotechnology company’s stock valued at $792,042,000 after purchasing an additional 121,072 shares in the last quarter. Finally, American Century Companies Inc. boosted its stake in shares of Biogen by 32.1% in the 3rd quarter. American Century Companies Inc. now owns 1,507,871 shares of the biotechnology company’s stock valued at $532,746,000 after purchasing an additional 366,361 shares in the last quarter. 86.94% of the stock is owned by institutional investors.

Several research analysts recently weighed in on the stock. Leerink Swann set a $340.00 price target on shares of Biogen and gave the stock a “hold” rating in a report on Wednesday, October 24th. BidaskClub upgraded shares of Biogen from a “sell” rating to a “hold” rating in a report on Tuesday, November 6th. Oppenheimer set a $380.00 price target on shares of Biogen and gave the stock a “buy” rating in a report on Sunday, October 28th. Mizuho set a $427.00 price target on shares of Biogen and gave the stock a “buy” rating in a report on Tuesday, October 23rd. Finally, Sanford C. Bernstein lowered shares of Biogen from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $373.00 to $341.00 in a research report on Friday, October 19th. Eight investment analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has issued a strong buy rating to the company’s stock. Biogen has an average rating of “Buy” and a consensus price target of $379.53.

ILLEGAL ACTIVITY WARNING: “Biogen Inc (BIIB) Director Alexander J. Denner Purchases 30,000 Shares” was originally reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.watchlistnews.com/biogen-inc-biib-director-alexander-j-denner-purchases-30000-shares/2793727.html.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy.

Further Reading: How Does the Quiet Period Work?

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.